jpm
Most Read
After a single patient drives a big stock surge, Patrick Soon-Shiong makes his case to investors
At JPM, a debate on Alzheimer’s disease, some family drama in oncology, and a beaten-down biotech
All talk, no M&A makes for a down JPM Day
Agios CEO forecasts ‘line of sight’ to more approved drugs and profits
A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down
The ghosts of JPMs past: How 20 years of deals, scandal, and science have shaped health care
Virtual Event – [email protected]: Will 2022 bring biotech renewal?
All Coverage
advertisement
